Immune status following alemtuzumab treatment in human CD52 transgenic mice. Turner MJ, Lamorte MJ, Chretien N, Havari E, Roberts BL, Kaplan JM, Siders WM J Neuroimmunol. 2013 Jun 4. PMID: 23759318. Abstract CommentRecommendBookmarkWatch